Hikma Set For Ryaltris Take Off As Glenmark Wins USFDA Nod
Companies Partnered Up In March 2020; Ryaltris Already Rolled-Out In Europe
Executive Summary
Glenmark is celebrating a “major milestone,” after its Ryaltris nasal spray to treat seasonal allergic rhinitis was approved by the FDA. Hikma will handle commercialization in the US, as part of its continued specialty push in the market.
You may also be interested in...
Glenmark’s Ryaltris ‘Ahead Of The Game’ In Markets, COVID-19 Nasal Spray Coming
There is momentum for Glenmark’s Ryaltris across new launch markets internationally, with FY2023 and FY2024 seen as important years for revenue scale-up. A partnered nitric oxide nasal spray for COVID-19 faces trial recruitment challenges in India but the firm hopes to be able to debut the product this year.
Hikma’s Olafsson Offers Latest On Advair And Vascepa Rivals
Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.
Hikma Strikes Deal For Ryaltris In US
Hikma has struck a deal with Glenmark to gain US rights to its Ryaltris nasal spray. The agreement comes as Hikma reported sales ahead by 7% in 2019 on strong performances from the firm’s Injectables and Branded segments.